These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33631080)

  • 41. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
    Áñez G; Hedrick J; Simon MW; Christensen S; Jeanfreau R; Yau E; Pan J; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2020 Jun; 16(6):1292-1298. PubMed ID: 32209015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program.
    Bos JM; Rümke HC; Welte R; Postma MJ; Jager JC
    Vaccine; 2001 Oct; 20(1-2):202-7. PubMed ID: 11567765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Bilukha OO; Rosenstein N;
    MMWR Recomm Rep; 2005 May; 54(RR-7):1-21. PubMed ID: 15917737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
    Beck E; Klint J; Neine M; Garcia S; Meszaros K
    Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada.
    Breton MC; Huang L; Snedecor SJ; Cornelio N; Fanton-Aita F
    Can J Public Health; 2020 Apr; 111(2):182-192. PubMed ID: 31907760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces.
    Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J
    Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
    BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of invasive meningococcal disease in university students in England and optimal strategies for protection using MenACWY vaccine.
    Mandal S; Campbell H; Ribeiro S; Gray S; Carr T; White J; Ladhani SN; Ramsay ME
    Vaccine; 2017 Oct; 35(43):5814-5818. PubMed ID: 28928076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meningococcal conjugate vaccine uptake, measured by Michigan's immunization registry.
    Enger KS; Stokley S
    J Adolesc Health; 2007 May; 40(5):398-404. PubMed ID: 17448396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.
    Scott RD; Meltzer MI; Erickson LJ; De Wals P; Rosenstein NE
    Am J Prev Med; 2002 Aug; 23(2):98-105. PubMed ID: 12121797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.
    Bos JM; Rümke H; Welte R; Postma MJ
    Clin Ther; 2003 Oct; 25(10):2614-30. PubMed ID: 14667962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
    Bousema JC; Ruitenberg J
    Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine.
    Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Oster P; Borrow R
    Vaccine; 2014 Sep; 32(43):5715-21. PubMed ID: 25151042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Information needs during an emerging outbreak of meningococcal W135 disease in the Netherlands: a study among teenagers, their parents and healthcare professionals.
    de Vries M; Çoban FR; Claassen L; Te Wierik MJM; Timmermans DRM; Timen A
    BMC Public Health; 2021 Aug; 21(1):1540. PubMed ID: 34380443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.